Edna Frances Roche
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Edna Frances Roche has a total of 378 co-authors. Here are the top co-authors by number of shared publications:
- Montasser Nadeem
Department of Paediatrics, NCH, Tallaght, Dublin 24
10 shared publications - Rikke Beck Jensen
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
8 shared publications - Anders Juul
Department of Growth and Reproduction Copenhagen University Hospital ‐ Rigshospitalet Copenhagen Denmark
7 shared publications Hilary Hoey
The Department of Paediatrics Trinity College Dublin The University of Dublin Dublin Ireland
7 shared publicationsOlle Söder
Pediatric Endocrinology Unit, Department of Women's and Children's Health, Karolinska Institute , 17177 Stockholm , Sweden
7 shared publications- Hilary Hoey
Department of Pediatrics, CHI at Tallaght University Hospital, Trinity College Dublin, The University of Dublin , Dublin 24 , Ireland
6 shared publications
Latest Publications
- Open Access
- 13 January 2026
- Published by BMJ in BMJ Public Health
- Vol. 4 (1) , e003056
Estimating national prevalence of type 1 diabetes mellitus in children in Ireland using a novel simple approach: an observational study
Introduction: Diabetes mellitus type 1 or type 1 diabetes (T1D) is a common life-threatening autoimmune condition in children with accurate estimates of those affected required for appropriate healthcare planning. While the incidence of T1D is prospectively monitored by the Irish Childhood Diabetes National Register (ICDNR), to date there are limited data regarding its prevalence. This study aims to develop a simple, reusable method of estimating population disease prevalence, here applied to Irish childhood T1D. Methods: Using robust ICDNR national annual incidence data from 2008 to 2021, for T1D in children aged under 15 years, a simulation-based model was developed, assuming normal distributions for age-specific rates beyond the first year of life. Using this model, the number of children with T1D was calculated and accuracy was assessed through bootstrapping. This estimate was compared with the measured prevalence using incidence data reported to the ICDNR for those diagnosed and aged under 15 years from 1 January 2008 to 31 December 2022 and 1 January 2009 to 31 December 2023. Results: Applying this simulation model, the estimated number of children with T1D in Ireland in 2021 ranged between 1952 and 2050, yielding a national prevalence range of 0.20%–0.21%. The measured prevalence in 2022 and 2023, using cumulative incidence, was comparable and stable over the 2-year period at 2054 or 0.20%. Conclusions: This methodology serves as a practical tool to estimate the number affected by childhood T1D, critical for planning appropriate health services and allocating resources to meet their specific needs. This simple model can easily be applied to other populations or diseases with known incidence to estimate prevalence.
- 13 January 2026
- Published by BMJ in BMJ Public Health
- Vol. 4 (1) , e003056
Open AccessEstimating national prevalence of type 1 diabetes mellitus in children in Ireland using a novel simple approach: an observational study
Introduction: Diabetes mellitus type 1 or type 1 diabetes (T1D) is a common life-threatening autoimmune condition in children with accurate estimates of those affected required for appropriate healthcare planning. While the incidence of T1D is prospectively monitored by the Irish Childhood Diabetes National Register (ICDNR), to date there are limited data regarding its prevalence. This study aims to develop a simple, reusable method of estimating population disease prevalence, here applied to Irish childhood T1D. Methods: Using robust ICDNR national annual incidence data from 2008 to 2021, for T1D in children aged under 15 years, a simulation-based model was developed, assuming normal distributions for age-specific rates beyond the first year of life. Using this model, the number of children with T1D was calculated and accuracy was assessed through bootstrapping. This estimate was compared with the measured prevalence using incidence data reported to the ICDNR for those diagnosed and aged under 15 years from 1 January 2008 to 31 December 2022 and 1 January 2009 to 31 December 2023. Results: Applying this simulation model, the estimated number of children with T1D in Ireland in 2021 ranged between 1952 and 2050, yielding a national prevalence range of 0.20%–0.21%. The measured prevalence in 2022 and 2023, using cumulative incidence, was comparable and stable over the 2-year period at 2054 or 0.20%. Conclusions: This methodology serves as a practical tool to estimate the number affected by childhood T1D, critical for planning appropriate health services and allocating resources to meet their specific needs. This simple model can easily be applied to other populations or diseases with known incidence to estimate prevalence.
- 18 September 2025
- Published by Springer Nature in Pediatric Research
- Vol. 99 (1) , 34-35
Turning the tide on gestational diabetes mellitus to protect social-emotional development
- 18 September 2025
- Published by Springer Nature in Pediatric Research
- Vol. 99 (1) , 34-35
Turning the tide on gestational diabetes mellitus to protect social-emotional development
- Open Access
- 22 May 2024
- Published by Elsevier in Global Pediatrics
- Vol. 9
Advances in undergraduate and postgraduate education- bedside, simulation and E-learning
- 22 May 2024
- Published by Elsevier in Global Pediatrics
- Vol. 9
Open AccessAdvances in undergraduate and postgraduate education- bedside, simulation and E-learning
- Open Access
- 8 August 2023
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 182 (10) , 4615-4623
The incidence of type 1 diabetes in children under 15 years of age is rising again—a nationwide study
International incidence rates (IRs) and trends of childhood type 1 diabetes (T1D) vary. Recent data from Ireland and other high incidence countries suggested a stabilisation in IRs of T1D in children aged under 15 years. Our primary objective was to report the IR of T1D in children in Ireland from 2019 to 2021 and evaluate if age, sex and season of diagnosis had changed. Incident cases of T1D in those aged under 15 years were identified prospectively by clinicians nationally and reported to the Irish Childhood Diabetes National Register (ICDNR). Following case verification, capture-recapture methodology was applied, and IRs calculated. Numbers of children including age, sex and season of diagnosis per year were evaluated. There were 1027 cases, 542 males (53%). The direct standardised incidence rates (SIRs) increased by 21% overall and were 31.1, 32.2 and 37.6/100,000/year, respectively, with no significant sex difference. The highest IRs were in the 10–14-year category until 2021, then changed to the 5–9-year category (40% of cases). Whilst autumn and winter remain dominant diagnostic seasons, seasonality differed in 2021 with a greater number presenting in spring.Conclusion: The incidence of childhood T1D in Ireland is increasing, observed prior to the COVID-19 pandemic, and shifting to an earlier age at diagnosis for the first time. The pattern of seasonality also appears to have changed. This may reflect an increased severity of diabetes with important implications for healthcare providers. What is Known:• Ireland has a very high incidence of T1D in childhood, which had stabilised following a rapid rise, similar to other high incidence countries.• The incidence rate is consistently highest in older children (10–14 years). What is New:• Irish IR is no longer stable and has increased again, with the highest incidence occurring in the younger 5-9 age category for the first time.• The seasonality of diagnosis has changed during the COVID-19 pandemic years of 2020–2021.
- 8 August 2023
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 182 (10) , 4615-4623
Open AccessThe incidence of type 1 diabetes in children under 15 years of age is rising again—a nationwide study
International incidence rates (IRs) and trends of childhood type 1 diabetes (T1D) vary. Recent data from Ireland and other high incidence countries suggested a stabilisation in IRs of T1D in children aged under 15 years. Our primary objective was to report the IR of T1D in children in Ireland from 2019 to 2021 and evaluate if age, sex and season of diagnosis had changed. Incident cases of T1D in those aged under 15 years were identified prospectively by clinicians nationally and reported to the Irish Childhood Diabetes National Register (ICDNR). Following case verification, capture-recapture methodology was applied, and IRs calculated. Numbers of children including age, sex and season of diagnosis per year were evaluated. There were 1027 cases, 542 males (53%). The direct standardised incidence rates (SIRs) increased by 21% overall and were 31.1, 32.2 and 37.6/100,000/year, respectively, with no significant sex difference. The highest IRs were in the 10–14-year category until 2021, then changed to the 5–9-year category (40% of cases). Whilst autumn and winter remain dominant diagnostic seasons, seasonality differed in 2021 with a greater number presenting in spring.Conclusion: The incidence of childhood T1D in Ireland is increasing, observed prior to the COVID-19 pandemic, and shifting to an earlier age at diagnosis for the first time. The pattern of seasonality also appears to have changed. This may reflect an increased severity of diabetes with important implications for healthcare providers. What is Known:• Ireland has a very high incidence of T1D in childhood, which had stabilised following a rapid rise, similar to other high incidence countries.• The incidence rate is consistently highest in older children (10–14 years). What is New:• Irish IR is no longer stable and has increased again, with the highest incidence occurring in the younger 5-9 age category for the first time.• The seasonality of diagnosis has changed during the COVID-19 pandemic years of 2020–2021.
- 25 April 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 108 (10) , e1161
Response to Letter to the Editor From Arroyo et al: “Timing of Puberty, Pubertal Growth, and Adult Height in Short Children Born Small for Gestational Age Treated With Growth Hormone”
Emmie N Upners, Lars Lau Raket, Jørgen H Petersen, Ajay Thankamony, Edna Roche, Guftar Shaikh, Jeremy Kirk, Hilary Hoey, Sten-A Ivarsson, Olle Söder, Anders Juu
- 25 April 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 108 (10) , e1161
Response to Letter to the Editor From Arroyo et al: “Timing of Puberty, Pubertal Growth, and Adult Height in Short Children Born Small for Gestational Age Treated With Growth Hormone”
Emmie N Upners, Lars Lau Raket, Jørgen H Petersen, Ajay Thankamony, Edna Roche, Guftar Shaikh, Jeremy Kirk, Hilary Hoey, Sten-A Ivarsson, Olle Söder, Anders Juu
- 6 May 2022
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (8) , 2286-2295
Timing of Puberty, Pubertal Growth, and Adult Height in Short Children Born Small for Gestational Age Treated With Growth Hormone
Context Growth hormone (GH) is used to treat short children born small for gestational age (SGA); however, the effects of treatment on pubertal timing and adult height are rarely studied. Objective To evaluate adult height and peak height velocity in short GH-treated SGA children. Methods Prospective longitudinal multicenter study. Participants were short children born SGA treated with GH therapy (n = 102). Adult height was reported in 47 children. A reference cohort of Danish children was used. Main outcome measures were adult height, peak height velocity, age at peak height, and pubertal onset. Pubertal onset was converted to SD score (SDS) using Danish reference data. Results Gain in height SDS from start of treatment until adult height was significant in both girls (0.94 [0.75; 1.53] SDS, P = .02) and boys (1.57 [1.13; 2.15] SDS, P < .001). No difference in adult height between GH dosage groups was observed. Peak height velocity was lower than a reference cohort for girls (6.5 [5.9; 7.6] cm/year vs 7.9 [7.4; 8.5] cm/year, P < .001) and boys (9.5 [8.4; 10.7] cm/year vs 10.1 [9.7; 10.7] cm/year, P = .002), but no difference in age at peak height velocity was seen. Puberty onset was earlier in SGA boys than a reference cohort (1.06 [–0.03; 1.96] SDS vs 0 SDS, P = .002) but not in girls (0.38 [–0.19; 1.05] SDS vs 0 SDS, P = .18). Conclusion GH treatment improved adult height. Peak height velocity was reduced, but age at peak height velocity did not differ compared with the reference cohort. SGA boys had an earlier pubertal onset compared with the reference cohort.
- 6 May 2022
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (8) , 2286-2295
Timing of Puberty, Pubertal Growth, and Adult Height in Short Children Born Small for Gestational Age Treated With Growth Hormone
Context Growth hormone (GH) is used to treat short children born small for gestational age (SGA); however, the effects of treatment on pubertal timing and adult height are rarely studied. Objective To evaluate adult height and peak height velocity in short GH-treated SGA children. Methods Prospective longitudinal multicenter study. Participants were short children born SGA treated with GH therapy (n = 102). Adult height was reported in 47 children. A reference cohort of Danish children was used. Main outcome measures were adult height, peak height velocity, age at peak height, and pubertal onset. Pubertal onset was converted to SD score (SDS) using Danish reference data. Results Gain in height SDS from start of treatment until adult height was significant in both girls (0.94 [0.75; 1.53] SDS, P = .02) and boys (1.57 [1.13; 2.15] SDS, P < .001). No difference in adult height between GH dosage groups was observed. Peak height velocity was lower than a reference cohort for girls (6.5 [5.9; 7.6] cm/year vs 7.9 [7.4; 8.5] cm/year, P < .001) and boys (9.5 [8.4; 10.7] cm/year vs 10.1 [9.7; 10.7] cm/year, P = .002), but no difference in age at peak height velocity was seen. Puberty onset was earlier in SGA boys than a reference cohort (1.06 [–0.03; 1.96] SDS vs 0 SDS, P = .002) but not in girls (0.38 [–0.19; 1.05] SDS vs 0 SDS, P = .18). Conclusion GH treatment improved adult height. Peak height velocity was reduced, but age at peak height velocity did not differ compared with the reference cohort. SGA boys had an earlier pubertal onset compared with the reference cohort.
- 21 February 2022
- Published by BMJ in Archives of Disease in Childhood
- Vol. 107 (4) , 409.1-411
Communicating a neonatal diagnosis of Down syndrome to parents
In a postnatal diagnosis of DS (population), what specific aspects of communication should be routinely implemented (intervention) which when compared with current reported methods of communication (comparison) provide more support to families (outcome)?
- 21 February 2022
- Published by BMJ in Archives of Disease in Childhood
- Vol. 107 (4) , 409.1-411
Communicating a neonatal diagnosis of Down syndrome to parents
In a postnatal diagnosis of DS (population), what specific aspects of communication should be routinely implemented (intervention) which when compared with current reported methods of communication (comparison) provide more support to families (outcome)?
- Open Access
- 30 September 2021
- Published by BMJ
- Vol. 106 (Suppl 1) , A341-A342
1369 Preliminary report of healthcare status in a cohort of young children aged 1–5 years with down syndrome
Background Ireland is thought to have amongst the highest incidence of Down syndrome (DS) in the world. Children with DS have many healthcare needs and associated conditions. DS medical management guidelines have been developed to optimise the health of children with DS. A national Register was established in 2015 to define the incidence of DS in the Irish population and undertake prospective monitoring of health issues and healthcare utilisation. Objectives The purpose of this study is to explore the health issues faced by young children with DS, both resolving and emergent. Methods Parents of children with DS aged between 1 to 5 years who were enrolled on the national DS Register were invited to complete a questionnaire. The questionnaire was self-administered, distributed to families by post between September 17th 2020 and January 28th 2021 and returned by post or email. It contained 15 questions including questions about new diagnoses (medical or surgical), resolved diagnoses, feeding issues, annual screening and hospital admissions in the preceding 12-month period and current parental perception of their child’s health. Ethical approval was obtained for this study. Results A total of 62 questionnaires have been distributed and 28 have been returned to date. Response rate was 45%. Mean age was 4 years (range 1–5 years) with female being 16/28 (57%). The majority of parents who replied rated their child’s health as excellent or very good (18/28 or 64%). In the preceding 12 months: at least one admission to hospital was required by 43%; a new condition was diagnosed in 12/27 (44%); a pre-existing condition had resolved in 11/23 (48%) such as improved hearing due to grommets or hearing aids and reduced aspiration due to peg insertion and improvement in respiratory issues possibly due to reduced social contact. Some of the reasons for admission were respiratory problems such as croup, bronchiolitis, aspiration pneumonia and also ear infections. Feeding issues were reported in 11/28 (39%) among them difficulty with solids, food aversions, sensory issues choking/aspiration and only one stated that their child had a Videofluroscopy in the last 12 months. Annual blood monitoring was undertaken in 27 out of the 28 patients and thyroid monitoring identified as being taken in 22/28 (78%) and coeliac as 14/28 (50%). The majority expressed concerns 21/28 (75%) regarding health issues, long term outcomes and service access. Services were self-funded by 12/28 (43%) of parents due to long waiting time for public services or due to low frequency of appointments. Conclusion This study demonstrated high levels of parental satisfaction with the health of their children with DS. Despite the SARS- CoV-2 pandemic a large number required hospitalisation. Almost half of the parents self-funded certain services although this may have been influenced by the international pandemic with restricted access to healthcare. These data will help inform healthcare service development and service provision for children with DS. Monitoring these issues over time will enhance our understanding of any underlying problems and improve the care we provide for children with Down syndrome and their families.
- 30 September 2021
- Published by BMJ
- Vol. 106 (Suppl 1) , A341-A342
Open Access1369 Preliminary report of healthcare status in a cohort of young children aged 1–5 years with down syndrome
Background Ireland is thought to have amongst the highest incidence of Down syndrome (DS) in the world. Children with DS have many healthcare needs and associated conditions. DS medical management guidelines have been developed to optimise the health of children with DS. A national Register was established in 2015 to define the incidence of DS in the Irish population and undertake prospective monitoring of health issues and healthcare utilisation. Objectives The purpose of this study is to explore the health issues faced by young children with DS, both resolving and emergent. Methods Parents of children with DS aged between 1 to 5 years who were enrolled on the national DS Register were invited to complete a questionnaire. The questionnaire was self-administered, distributed to families by post between September 17th 2020 and January 28th 2021 and returned by post or email. It contained 15 questions including questions about new diagnoses (medical or surgical), resolved diagnoses, feeding issues, annual screening and hospital admissions in the preceding 12-month period and current parental perception of their child’s health. Ethical approval was obtained for this study. Results A total of 62 questionnaires have been distributed and 28 have been returned to date. Response rate was 45%. Mean age was 4 years (range 1–5 years) with female being 16/28 (57%). The majority of parents who replied rated their child’s health as excellent or very good (18/28 or 64%). In the preceding 12 months: at least one admission to hospital was required by 43%; a new condition was diagnosed in 12/27 (44%); a pre-existing condition had resolved in 11/23 (48%) such as improved hearing due to grommets or hearing aids and reduced aspiration due to peg insertion and improvement in respiratory issues possibly due to reduced social contact. Some of the reasons for admission were respiratory problems such as croup, bronchiolitis, aspiration pneumonia and also ear infections. Feeding issues were reported in 11/28 (39%) among them difficulty with solids, food aversions, sensory issues choking/aspiration and only one stated that their child had a Videofluroscopy in the last 12 months. Annual blood monitoring was undertaken in 27 out of the 28 patients and thyroid monitoring identified as being taken in 22/28 (78%) and coeliac as 14/28 (50%). The majority expressed concerns 21/28 (75%) regarding health issues, long term outcomes and service access. Services were self-funded by 12/28 (43%) of parents due to long waiting time for public services or due to low frequency of appointments. Conclusion This study demonstrated high levels of parental satisfaction with the health of their children with DS. Despite the SARS- CoV-2 pandemic a large number required hospitalisation. Almost half of the parents self-funded certain services although this may have been influenced by the international pandemic with restricted access to healthcare. These data will help inform healthcare service development and service provision for children with DS. Monitoring these issues over time will enhance our understanding of any underlying problems and improve the care we provide for children with Down syndrome and their families.
- Open Access
- 10 March 2021
- Published by Wiley in Acta Paediatrica
- Vol. 110 (7) , 2142-2148
Incidence of childhood type 1 diabetes mellitus in Ireland remains high but no longer rising
Aim: The global incidence of type 1 diabetes mellitus (T1DM) varies considerably geographically. Ireland has a high incidence of T1DM. Incidence accelerated between 1997 and 2008, although more recent data (2008–2013) suggested stabilisation in the incidence rate (IR). This study sought to determine IRs for 2014 to 2018.Methods: Incident cases were prospectively recorded through the established Irish Childhood Diabetes National Register (ICDNR). Cases were verified, and IRs were calculated. Capture‐recapture methodology was identical to previous studies. Age and seasonality data were compared.Results: A total of 1429 cases were reported (age range 0.45–14.98 years), with significantly more males (772, 54%) and male‐to‐female ratio of 1.17 (95% CI 1.05, 1.29). Standardised IRs for T1DM in the period were 28.0; 29.6; 30.9; 27.0; and 27.1/100,000/year, respectively. There was a slight reduction in standardised IR, more marked in females than males (9.9% v 1.6%). The highest IR remains in the 10‐ to 14‐year‐old age group (44% of total cases). Seasonality of diagnosis is persistently higher in autumn and winter.Conclusion: Ireland remains a high incidence country, despite a minor reduction in incidence rates. Ongoing incidence monitoring through national registers is vital to inform healthcare services, research relating to aetiology and paediatric diabetes management.
- 10 March 2021
- Published by Wiley in Acta Paediatrica
- Vol. 110 (7) , 2142-2148
Open AccessIncidence of childhood type 1 diabetes mellitus in Ireland remains high but no longer rising
Aim: The global incidence of type 1 diabetes mellitus (T1DM) varies considerably geographically. Ireland has a high incidence of T1DM. Incidence accelerated between 1997 and 2008, although more recent data (2008–2013) suggested stabilisation in the incidence rate (IR). This study sought to determine IRs for 2014 to 2018.Methods: Incident cases were prospectively recorded through the established Irish Childhood Diabetes National Register (ICDNR). Cases were verified, and IRs were calculated. Capture‐recapture methodology was identical to previous studies. Age and seasonality data were compared.Results: A total of 1429 cases were reported (age range 0.45–14.98 years), with significantly more males (772, 54%) and male‐to‐female ratio of 1.17 (95% CI 1.05, 1.29). Standardised IRs for T1DM in the period were 28.0; 29.6; 30.9; 27.0; and 27.1/100,000/year, respectively. There was a slight reduction in standardised IR, more marked in females than males (9.9% v 1.6%). The highest IR remains in the 10‐ to 14‐year‐old age group (44% of total cases). Seasonality of diagnosis is persistently higher in autumn and winter.Conclusion: Ireland remains a high incidence country, despite a minor reduction in incidence rates. Ongoing incidence monitoring through national registers is vital to inform healthcare services, research relating to aetiology and paediatric diabetes management.
- Open Access
- 1 September 2020
- Published by Elsevier in European Urology Open Science
- Vol. 20, S25
Sarcopenia and Body Composition Analysis – Initial Results of a Urological Surgery Cohort
- 1 September 2020
- Published by Elsevier in European Urology Open Science
- Vol. 20, S25
Open AccessSarcopenia and Body Composition Analysis – Initial Results of a Urological Surgery Cohort